For a patient with relapsed FLT3 positive AML on HMA and venetoclax, is there ever a role for the addition of midostaurin to the treatment regimen to improve response rate?

Short answer is no. The safety of the combination is unknown and there’s also not an indication for Midostaurin in relapsed AML. The trial that got Midostaurin approved was for combination with 7+3 in newly diagnosed patients. HMA+ venetoclax has better response frontline compared to relapsed/refractory. Gilteritinib is a FLT3 inhibitor now approved as in relapsed disease. Trials are ongoing in combination with HMA or of other agents.